Ключевые слова:
metabolik sindrom, insulin rezistentlik, jigar, adipokinlar, giperglikemiya, dislipidemiya.Библиографические ссылки
Grundy S.M. Metabolic Syndrome: A multiplex cardiovascular risk factor // J. Clin. Endocrinol. Metab. – 2020. – Vol. 105, №5. – P. e1835-e1844.
Reaven G. Insulin resistance: the link between obesity and cardiovascular disease // Med. Clin. North Amer. – 1988. – Vol. 72, №1. – P. 79-101.
Eslam M. et al. MAFLD: a consensus-driven redefinition of fatty liver disease // Gastroenterology. – 2020. – Vol. 158, №7. – P. 1999-2014.
EASL-EASD-EASO. Clinical Practice Guidelines for the management of NAFLD // J. Hepatol. – 2023. – Vol. 79, №3. – P. 610-647.
Saklayen M.G. The global epidemic of the metabolic syndrome // Curr. Hypertens. Rep.. – 2018. – Vol. 20, №2. – Article 12.
Hasanova S.R. Metabolik sindrom: klinik ko‘rinishlar va diagnostik yondashuvlar // O‘zbekiston tibbiyot jurnali. – 2023. – №1. – B. 22-26.
DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links // Diabetologia. – 2021. – Vol. 64, №6. – P. 1105-1115.
Samuel V.T., Shulman G.I. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases // Cell Metab. – 2022. – Vol. 34, №6. – P. 805-822.
Kadowaki T. et al. The role of adiponectin and adiponectin receptors in obesity-related insulin resistance // Nat. Rev. Endocrinol. – 2020. – Vol. 16, №6. – P. 350-365.
Ferrannini E. et al. Atherogenic dyslipidemia and insulin resistance: mechanisms and therapeutic approaches // Cardiovasc. Diabetol. – 2021. – Vol. 20. – Article 52.
Esser N. et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes // Diab. Res. Clin. Pract. – 2020. – Vol. 110, №1. – P. 11-18.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and consequence of metabolic syndrome // Lancet Diab. Endocrinol. – 2023. – Vol. 11, №1. – P. 15-30.
Gaggini M. et al. Pathophysiology of liver disease in the metabolic syndrome // Best Pract. Res. Clin. Endocrinol. Metab. – 2023. – Vol. 37, №1. – Р. 101679.
Yki-Järvinen H. NAFLD as a cause and consequence of metabolic syndrome // Lancet Diab. Endocrinol. – 2023. – Vol. 11, №1. – P. 15-30.
Samuel V.T., Shulman G.I. Mechanisms for insulin resistance in liver // Cell Metab. – 2022. – Vol. 34, №6. – P. 805-822.
Bril F., Cusi K. Hepatic insulin resistance and NAFLD: causes and consequences // Diabetologia. – 2021. – Vol. 64, №6. – P. 1121-1131.
Younossi Z.M. et al. Global perspectives on NAFLD and NASH // Hepatology. – 2021. – Vol. 73, №1. – P. 18-38.
Eslam M. et al. MAFLD: a consensus-driven redefinition of fatty liver disease // Gastroenterology. – 2020. – Vol. 158, №7. – P. 1999-2014.
Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity // Nature Reviews Immunology. – 2020. – Vol. 20. – P. 77–92.
Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors in disease and aging // Nat. Rev. Drug Dis. – 2021. – Vol. 20, №3. – P. 193-212.
Zhang Y. et al. Positional cloning of the mouse obese gene and its human homologue // Nature. – 2020. – Vol. 372. – P. 425-432.
Polyzos S.A. et al. Leptin in nonalcoholic fatty liver disease: a narrative review // Metabolism. – 2021. – Vol. 115. – 154455.
Xu A. et al. Adiponectin ameliorates dyslipidemia induced by high-fat diet in mice through its anti-inflammatory action // Biochem J. – 2022. – Vol. 446, №1. – P. 1-8.